Triple
T21132314
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Abellio (Celtic deity) |
E520718
|
entity |
| Predicate | nameVariant |
P744
|
FINISHED |
| Object | Abellion |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Abellion | Statement: [Abellio (Celtic deity), nameVariant, Abellion]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Abellion Context triple: [Abellio (Celtic deity), nameVariant, Abellion]
-
A.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
B.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
-
C.
Ambrx
Ambrx is a biotechnology company specializing in engineered biologics and next-generation antibody-drug conjugates using expanded genetic code technology.
-
D.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
E.
Sygnaq
Sygnaq was a historic Central Asian city that served as an important political and trade center, notably functioning as the capital of the Kazakh Khanate.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Abellion Target entity description: Abellion is a Celtic deity, likely associated with the sun or light, venerated in the region of ancient Aquitania.
-
A.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
B.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
-
C.
Ambrx
Ambrx is a biotechnology company specializing in engineered biologics and next-generation antibody-drug conjugates using expanded genetic code technology.
-
D.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
E.
Sygnaq
Sygnaq was a historic Central Asian city that served as an important political and trade center, notably functioning as the capital of the Kazakh Khanate.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e0b50b53048190ae34e8abbe3c5ada |
completed | April 16, 2026, 10:08 a.m. |
| NER | Named-entity recognition | batch_69e723574b1481909fe9bebc83f1f3ce |
completed | April 21, 2026, 7:12 a.m. |
Created at: April 16, 2026, 2:56 p.m.